1. A universal TLR7-nanoparticle adjuvant promotes broad immune responses against heterologous strains of Influenza and SARS-CoV-2
- Author
-
Meng Sun, Rohit Verma, Jing Li, Neha Gupta, Yang Bo, Oliver Kask, Christian McCrory Constantz, Jing Guo, Wei Luo, Jianghong Rao, Yueh-hsiu Chien, Lisa E. Wagar, Jianjun Cheng, Jinghang Xie, Bali Pulendran, Elsa Solà, Mark M. Davis, Venkata Vamsee Aditya Mallajosyula, and Qian Yin
- Subjects
Immune system ,medicine.medical_treatment ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine ,virus diseases ,Heterologous ,TLR7 ,Biology ,Adjuvant ,Virology - Abstract
Fully effective vaccines for viruses such as Influenza and SARS-CoV-2 must elicit a diverse repertoire of antibodies against multiple drifted virus strains. However, how to achieve a diverse response has no general solution except to combine multiple strains, which risks diluting the response for all strains included. Here, we describe the synthesis of a universal, toll-like receptor 7 agonist (TLR7)-nanoparticle adjuvant, TLR7-NP, constructed from TLR7 agonist-initiated ring-opening polymerization of lactide and self-assembly with poly(ethylene glycol)-b-poly(lactic-co-glycolic acid). When mixed with Alum-adsorbed antigens, this TLR7-NP adjuvant elicited cross-reactive antibodies for both dominant and subdominant epitopes, as well as antigen-specific CD8+ T cell responses. TLR7-NPs adjuvanted influenza subunit vaccine successfully protected mice from heterologous viral challenge. TLR7-NPs also enhanced the antibody response to a SARS-CoV-2 subunit vaccine against multiple variants and revealed the mobilization of a virus-like response. We further demonstrate enhanced antigen-specific responses in human tonsil organoids with this novel adjuvant.
- Published
- 2021
- Full Text
- View/download PDF